Physician profile
Michelle Hoadley
NPI 1497175327
$1,664.67
in general payments reported to CMS, 2019-2025
21 companies · $602 in 2025
The $602 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.06 · 2023: $173 · 2024: $808 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,582.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $239.77 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $169.07 | 2023-2025 | Trelegy Ellipta, Bexsero, Rotarix |
| Exact Sciences Corporation | $147.16 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $131.98 | 2024-2025 | Rybelsus, Ozempic |
| Shield Therapeutics INC | $130.66 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $97.80 | 2024-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Dexcom, INC. | $96.71 | 2024-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $95.43 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.98 | 2019-2025 | Jardiance, Tradjenta, Glyxambi |
| Abbott Laboratories | $81.04 | 2023-2025 | Freestyle Libre 3 |
| Cequr Corporation | $75.49 | 2024-2025 | Cequr Simplicity |
| Idorsia Pharmaceuticals US INC | $46.37 | 2023-2024 | Quviviq |
| Aimmune Therapeutics, INC. | $44.40 | 2024 | |
| Amgen INC. | $41.06 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $36.13 | 2024 | Farxiga, Airsupra |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $29.24 | 2024-2025 | Korlym |
| Abbvie INC. | $27.76 | 2025 | |
| Sanofi Pasteur INC. | $25.58 | 2024 | |
| Indivior INC. | $22.46 | 2023 | Perseris |
| Nestle Healthcare Nutrition INC. | $19.67 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $14.91 | 2024 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Hoadley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.